Remove topics inequitable-conduct
article thumbnail

Duty of Disclosure Before USPTO Highlighted in Federal Register

LexBlog IP

Director Vidal highlights four different topics as they relate to the duty of disclosure standard: 1. 2021), the courts found that the chief science officer acted inequitably when the submissions made to the FDA were inconsistent with the positions taken at the USPTO. Who Has a Duty to Disclose. Acorn Mobility Services, Ltd.

article thumbnail

Patent Law at the Supreme Court February 2022

Patently-O

The Kessler Doctrine : If you want to really dig into this case, please read my article on the topic that I wrote for an Akron Law review IP symposium issue. In the case, the patentee lost due to inequitable conduct. The invention in Yu was a multi-lens camera deemed abstract by the Federal Circuit. 2022)(forthcoming).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The United States Copyright Office Notice of Inquiry on AI: A Quick Take

Velocity of Content

On the assumption that readers might be interested in this topic and less interested in reviewing all the responses, I have pasted below a selection of questions and answers from Copyright Clearance Center’s (CCC’s) own response. With 34 questions asked about both copyright and technology, some parties responses exceed 100 pages.

article thumbnail

SpicyIP Weekly Review (August 23 – 29)

SpicyIP

Topical Highlight. She suggests that the IPD Rules should provide for penalties for bad faith conduct of parties such as filing frivolous applications and pleadings which unnecessarily draw out the proceedings. Thus, the Court held that the mandatory injunction granted by the Single Judge was inequitable. Sun Pharma v.

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., at ¶ 141.). Additional motions remain pending. Alvotech hf.